WallStSmart

Nasdaq Inc (NDAQ)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nasdaq Inc generates 1927% more annual revenue ($5.25B vs $258.90M). NDAQ leads profitability with a 34.1% profit margin vs -15.5%. NDAQ earns a higher WallStSmart Score of 69/100 (B-).

NDAQ

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 8.5Value: 10.0Quality: 6.5
Piotroski: 5/9

ZEPP

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NDAQUndervalued (+44.4%)

Margin of Safety

+44.4%

Fair Value

$144.61

Current Price

$83.74

$60.87 discount

UndervaluedFair: $144.61Overvalued

Intrinsic value data unavailable for ZEPP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NDAQ3 strengths · Avg: 9.3/10
Profit MarginProfitability
34.1%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
47.6%10/10

Strong operational efficiency at 47.6%

EPS GrowthGrowth
47.6%8/10

Earnings expanding 47.6% YoY

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

NDAQ2 concerns · Avg: 4.0/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
28.0x4/10

Moderate valuation

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$216.30M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : NDAQ

The strongest argument for NDAQ centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 34.1% and operating margin at 47.6%. Revenue growth of 13.4% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : NDAQ

The primary concerns for NDAQ are PEG Ratio, P/E Ratio.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

NDAQ profiles as a mature stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.59 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor FINANCIAL DATA & STOCK EXCHANGES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NDAQ scores higher overall (69/100 vs 43/100), backed by strong 34.1% margins and 13.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nasdaq Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

Nasdaq, Inc. is an American multinational financial services corporation that owns and operates stock exchanges in the United States and Europe. It is headquartered in New York City.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?